The stock price of Applied Dna Sciences Inc (NASDAQ: APDN) has plunged by -11.46 when compared to previous closing price of 5.15, but the company has seen a -4.20% decline in its stock price over the last five trading sessions. accessnewswire.com reported 2025-06-30 that – Conducts 27% Workforce Reduction, Ceases Operations at Applied DNA Clinical Labs, Positions LineaRx for Growth – STONY BROOK, NY / ACCESS Newswire / June 30, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN), a leader in PCR-based DNA technologies, announced a strategic restructuring and realignment of resources to focus exclusively on its synthetic DNA manufacturing business, LineaRx. As part of actions undertaken, the Company implemented a workforce reduction of approximately 27% of headcount and has ceased operations at Applied DNA Clinical Labs (ADCL), a business that provides molecular and genetic testing services, effective June 27, 2025.
Is It Worth Investing in Applied Dna Sciences Inc (NASDAQ: APDN) Right Now?
The 36-month beta value for APDN is also noteworthy at 0.05. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for APDN is 0.51M, and at present, short sellers hold a 20.44% of that float. The average trading volume of APDN on July 02, 2025 was 105.39K shares.
APDN’s Market Performance
The stock of Applied Dna Sciences Inc (APDN) has seen a -4.20% decrease in the past week, with a -9.95% drop in the past month, and a -81.69% fall in the past quarter. The volatility ratio for the week is 7.39%, and the volatility levels for the past 30 days are at 14.17% for APDN. The simple moving average for the past 20 days is -7.69% for APDN’s stock, with a -96.91% simple moving average for the past 200 days.
Analysts’ Opinion of APDN
Many brokerage firms have already submitted their reports for APDN stocks, with ROTH Capital repeating the rating for APDN by listing it as a “Buy.” The predicted price for APDN in the upcoming period, according to ROTH Capital is $24 based on the research report published on February 12, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see APDN reach a price target of $14, previously predicting the price at $18. The rating they have provided for APDN stocks is “Buy” according to the report published on January 14th, 2021.
H.C. Wainwright gave a rating of “Buy” to APDN, setting the target price at $12 in the report published on December 18th of the previous year.
APDN Trading at -46.77% from the 50-Day Moving Average
After a stumble in the market that brought APDN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.83% of loss for the given period.
Stock Fundamentals for APDN
Current profitability levels for the company are sitting at:
- -3.44 for the present operating margin
- 0.41 for the gross margin
The net margin for Applied Dna Sciences Inc stands at -8.25. The total capital return value is set at -1.17. Equity return is now at value -141.39, with -66.28 for asset returns.
Based on Applied Dna Sciences Inc (APDN), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -28.06.
Currently, EBITDA for the company is -13.33 million with net debt to EBITDA at 0.5. When we switch over and look at the enterprise to sales, we see a ratio of -1.05. The receivables turnover for the company is 5.49for trailing twelve months and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.45.
Conclusion
In summary, Applied Dna Sciences Inc (APDN) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
